Dr. Mark Shlomchik is a UPMC Endowed Distinguished Professor and Chair of the Department of Immunology at the University of Pittsburgh. He is also a Founder and Chief Scientific Officer of BlueSphere Bio, a company working to create individualized T cell therapies for the treatment of cancer. Dr. Shlomchik’s lab focuses on systemic autoimmune diseases, long-lived B cell immunity, and immunopathogenesis. He talks about the role of toll-like receptors in lupus, how his autoimmune disease research led to potential cancer therapies, and starting a biotech company with his brother.
Read More
Dr. Hanover Matz is a Postdoctoral Fellow at the University of Maryland, who recently completed his PhD under the supervision of Dr. Helen Dooley. He discusses why sharks may have evolved adaptive immune systems, the role of T cells, mucosal immunity, and antibodies, and working with sharks in the lab.
Read More
Dr. Dario Vignali is the Frank Dixon Chair in Cancer Immunology and Vice Chair and Professor of Immunology at University of Pittsburgh School of Medicine.  His lab studies various aspects of T cell regulation, and recently generated a new mouse model to target conventional CD4 T cells.
Read More
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
Read More
Dr. Christopher Klebanoff is an Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Read More